Skip to main content
OpenTrials
Completed

NCT Number: NCT01809769

Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis

Two injections in total and 3 ml autologous adipose-tissue-derived stem cells(haMSCs) for each injection; time-points for intervention: 1) initial injection; 2) 3 weeks following initial injection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Department of Rheumatology,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China

Shanghai, Shanghai Municipality, 200127, China

About this study

Adipose (fat) tissue is removed by lipo-aspiration (this may take up to 40 minutes). The fat is processed on-site to isolate and obtain the MSCs,then proliferate them. The suspension of the cells is injected into the knee joint under ultrasound guidance. (about 20 minutes).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who understand and sign the consent form for this study.
  • Age: 40-70, males and females.
  • Clinical diagnosis of degenerative arthritis by Radiographic Criteria of Kellgren and Lawrence.
  • Patients who can't treat with traditional medication and need a arthroplasty.
  • Duration of pain over Grade 4(11-point numeric scale)> 4 months.

Exclusion criteria

  • Women who are pregnant or breast feeding or planning to become pregnant during the study.
  • Objects who administer with a anti-inflammatory drugs within 14 days prior to inclusion in the study.
  • History or current evidence of alcohol or drug abuse or is a recreational user of illicit drugs or prescription medications.
  • Treatment with intra-articular injection therapy within 2 months prior to screen.
  • Other joint diseases except degenerative arthritis : systemic or rheumatic or inflammatory chondropathy, chondrocalcinosis, hemachromatosis, inflammatory joint disease, avascular necrosis of the femoral head, Paget's disease, hemophilic arthropathy, infectional arthritis, Charcot's disease, villonodular synovitis, synovial chondromatosis.
  • Positive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg, Anti-HCV-Ab), Hepatitis C (Anti-HCV-Ab) and syphilis.
  • Serious pre-existing medical conditions like Cardiovascular Diseases, Renal Diseases, Liver Diseases, Endocrine Diseases, Cancer and Diabetes Mellitus.
  • Overweight expressed as body mass index (BMI) greater than 30 (obesity grade II).
  • Participation in another clinical trial or treatment with a different investigational product within 3 months prior to inclusion in the study.
  • Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria.

Treatment and study plan

Mesenchymal stem cells low-dose group

Biological

Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use

Other names: Adipose tissue derived mesenchymal stem cells

Mesenchymal stem cells mid-dose group

Biological

Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use

Other names: Adipose tissue derived mesenchymal stem cells

Mesenchymal stem cells high-dose group

Biological

Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use

Other names: Adipose tissue derived mesenchymal stem cells

Primary outcomes

  1. Recording of Adverse Events and Serious Adverse Events

    Time frame: 12 weeks

  2. Electrocardiogram

    Time frame: 9 weeks

  3. Vital signs

    Time frame: 9 weeks

  4. Physical examination

    Time frame: 9 weeks

  5. WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)

    Time frame: 24 months

  6. Laboratory tests

    Time frame: 9 weeks

    Routine blood and urine tests, hepatic and renal functions tests, blood lipid and glucose tests, immunologic tests

Secondary outcomes

  1. SF-36

    Time frame: 24 months

  2. NRS-11

    Time frame: 24 months

  3. The volume of articular cartilage

    Time frame: 24 months

Sponsors and collaborators

Lead sponsor

Shanghai AbelZeta Ltd.

Industry

Collaborators

  • RenJi Hospital

Registry information

Official study title

Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis by Intra-articular Injection: A PhaseⅠ/Ⅱa, Randomized and Double-blinded Clinical Trial

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Mar 13, 2013
Registry last updated
Apr 4, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.